The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone

TitleThe use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone
Publication TypeJournal Article
Year of Publication2005
AuthorsFlomenberg N, Devine SM, Dipersio JF, Liesveld JL, McCarty JM, Rowley SD, Vesole DH, Badel K, Calandra G
JournalBlood
Volume106
Issue5
Pagination1867 - 74
Date PublishedSep 1
Type of ArticleClinical Trial Randomized Controlled Trial Research Support, Non-U.S. Gov't
ISSN0006-4971 (Print) 0006-4971 (Linking)
Accession Number15890685
KeywordsAdolescent, Adult, Aged, Antigens, CD34 / analysis, Antineoplastic Combined Chemotherapy Protocols / *administration &, dosage / adverse effects / pharmacology, Drug Synergism, effects / pharmacology, Female, Granulocyte Colony-Stimulating Factor / *administration & dosage / adverse, Hematopoietic Stem Cell Mobilization / *methods, Heterocyclic Compounds / *administration & dosage / adverse, Humans, Male, Middle Aged
Abstract

Hematopoietic progenitor cells (HPCs) traffic to and are retained in the marrow through the trophic effects of the chemokine stromal cell-derived factor-1alpha (SDF-1alpha) binding to its receptor, CXC chemokine receptor 4 (CXCR4). AMD3100 reversibly inhibits SDF-1alpha/CXCR4 binding, and AMD3100 administration mobilizes CD34(+) cells into the circulation. We therefore tested the hypotheses that the combination of AMD3100 plus granulocyte colony-stimulating factor (G-CSF) (hereafter A + G) would be superior to G-CSF alone (hereafter G) in mobilizing hematopoietic progenitor cells (HPCs) and that A + G-mobilized cells would engraft as well as G-mobilized cells. The primary objective was to determine whether patients mobilized more progenitor cells per unit of blood volume of apheresis after A + G administration versus G alone. Secondary objectives were to determine whether patients mobilized with A + G compared with G alone required fewer apheresis procedures to reach the target level at least 5 x 10(6) CD34(+) cells/kg for transplantation and to determine whether patients mobilized with A + G had at least a 90% success rate of autologous transplantation as assessed by neutrophil engraftment by day 21. Each patient served as his or her own control in a sequential mobilization design. All study objectives were met without significant toxicity. The results demonstrate that the combination of A + G is generally safe, effective, and superior to G alone for autologous HPC mobilization.

DOI10.1182/blood-2005-02-0468
Alternate JournalBlood
Notify Library Reference ID530

Related Incidents